Pharmacokinetic interaction of intravenous fentanyl with ketoconazole

Victoria C. Ziesenitz; Sonja K. König; Nina S. Mahlke; Gisela Skopp; Walter E. Haefeli; Gerd Mikus

doi:10.1002/jcph.469

journal article Feb 16, 2015

Pharmacokinetic interaction of intravenous fentanyl with ketoconazole

Victoria C. Ziesenitz Sonja K. König Nina S. Mahlke Gisela Skopp Walter E. Haefeli Gerd Mikus

The Journal of Clinical Pharmacology Vol. 55 No. 6 pp. 708-717 · Wiley

View at Publisher Save 10.1002/jcph.469

Topics

No keywords indexed for this article. Browse by subject →

References

42

[1]

Stanley "The history and development of the fentanyl series" J Pain Symptom Manage (1992) 10.1016/0885-3924(92)90047-l

[2]

Mather "Clinical pharmacokinetics of fentanyl and its newer derivatives" Clin Pharmacokinet (1983) 10.2165/00003088-198308050-00004

[3]

Paech "New formulations of fentanyl for acute pain management" Drugs Today (Barc) (2012) 10.1358/dot.2012.48.2.1745275

[4]

2013 https://www.incb.org/incb/en/narcotic-drugs/Technical_Reports/2013/narcotic-drugs-technical-report-2013

[5]

Uniform assessment and ranking of opioid Mu receptor binding constants for selected opioid drugs

Donna A. Volpe, Grainne A. McMahon Tobin, R. Daniel Mellon et al.

Regulatory Toxicology and Pharmacology 2011 10.1016/j.yrtph.2010.12.007

[6]

Feierman "Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes. Role of CYP3A4" Drug Metab Dispos (1996) 10.1016/s0090-9556(25)07486-0

[7]

Tateishi "Identification of human liver cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation" Anesth Analg (1996)

[8]

Takashina "Impact of CYP3A5 and ABCB1 gene polymorphisms on fentanyl pharmacokinetics and clinical responses in cancer patients undergoing conversion to a transdermal system" Drug Metab Pharmacokinet (2012) 10.2133/dmpk.dmpk-11-rg-134

[9]

Labroo "Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3 A4: implications for interindividual variability in disposition, efficacy, and drug interactions" Drug Metab Dispos (1997)

[10]

Hallberg "Possible fluconazole-fentanyl interaction-a case report" Eur J Clin Pharmacol (2006) 10.1007/s00228-006-0120-4

[11]

Horton "Opioid-induced respiratory depression resulting from transdermal fentanyl-clarithromycin drug interaction in a patient with advanced COPD" J Pain Symptom Manage (2009) 10.1016/j.jpainsymman.2009.02.230

[12]

Levin "Case report: delirium due to a diltiazem-fentanyl CYP3A4 drug interaction" Gen Hosp Psychiatry (2010) 10.1016/j.genhosppsych.2010.08.003

[13]

Mercadante "Itraconazole-fentanyl interaction in a cancer patient" J Pain Symptom Manage (2002) 10.1016/s0885-3924(02)00477-3

[14]

Ibrahim "Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil" Anesthesiology (2003) 10.1097/00000542-200304000-00011

[15]

Olkkola "Ritonavir's role in reducing fentanyl clearance and prolonging its half-life" Anesthesiology (1999) 10.1097/00000542-199909000-00020

[16]

Palkama "The CYP 3A4 inhibitor itraconazole has no effect on the pharmacokinetics of i.v. fentanyl" Br J Anaesth (1998) 10.1093/bja/81.4.598

[17]

Saari "Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl" Eur J Clin Pharmacol (2008) 10.1007/s00228-007-0398-x

[18]

Feierman "Identification of cytochrome P450 3A1/2 as the major P450 isoform responsible for the metabolism of fentanyl by rat liver microsomes" Anesth Analg (1996)

[19]

Hase "I.v. fentanyl decreases the clearance of midazolam" Br J Anaesth (1997) 10.1093/bja/79.6.740

[20]

Oda "Fentanyl inhibits metabolism of midazolam: competitive inhibition of CYP3A4 in vitro" Br J Anaesth (1999) 10.1093/bja/82.6.900

[21]

Mahlke "Quantitative low-volume assay for simultaneous determination of fentanyl, norfentanyl, and minor metabolites in human plasma and urine by liquid chromatography-tandem mass spectrometry (LC-MS/MS)" Int J Legal Med (2014) 10.1007/s00414-014-1040-y

[22]

Quintela "A sensitive, rapid and specific determination of midazolam in human plasma and saliva by liquid chromatography/electrospray mass spectrometry" Rapid Commun Mass Spectrom (2004) 10.1002/rcm.1719

[23]

Katzenmaier "Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using a limited sampling strategy" Clin Pharmacol Ther (2011) 10.1038/clpt.2011.164

[24]

Han "Fentanyl clearance and volume of distribution are increased in patients with major burns" J Clin Pharmacol (2007) 10.1177/0091270007299756

[25]

McClain "Intravenous fentanyl kinetics" Clin Pharmacol Ther (1980) 10.1038/clpt.1980.138

[26]

2011 http://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm#classInhibit

[27]

Clinically Important Drug Interactions Potentially Involving Mechanism-based Inhibition of Cytochrome P450 3A4 and the Role of Therapeutic Drug Monitoring

Shu-Feng Zhou, Charlie Changli Xue, Xue-Qing Yu et al.

Therapeutic Drug Monitoring 2007 10.1097/ftd.0b013e31815c16f5

[28]

Wilkinson "Clearance approaches in pharmacology" Pharmacol Rev (1987) 10.1016/s0031-6997(25)06653-0

[29]

Fuchs "Effect of the CYP3A inhibitor ketoconazole on the PXR-mediated induction of CYP3A activity" Eur J Clin Pharmacol (2013) 10.1007/s00228-012-1388-1

[30]

Halama "A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions" Clin Pharmacol Ther (2013) 10.1038/clpt.2013.27

[31]

Kronbach "Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4" Mol Pharmacol (1989) 10.1016/s0026-895x(25)09118-7

[32]

Lepper "Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients" Clin Cancer Res (2005) 10.1158/1078-0432.ccr-05-0520

[33]

General Framework for the Quantitative Prediction of CYP3A4-Mediated Oral Drug Interactions Based on the AUC Increase by Coadministration of??Standard Drugs

Yoshiyuki Ohno, Akihiro Hisaka, Hiroshi Suzuki

Clinical Pharmacokinetics 2007 10.2165/00003088-200746080-00005

[34]

Katzenmaier "Proposal of a new limited sampling strategy to predict CYP3A activity using a partial AUC of midazolam" Eur J Clin Pharmacol (2010) 10.1007/s00228-010-0878-2

[35]

Lee "Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping" Clin Pharmacol Ther (2002) 10.1067/mcp.2002.129068

[36]

Tsunoda "Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole" Clin Pharmacol Ther (1999) 10.1016/s0009-9236(99)70009-3

[37]

Stoch "Effect of different durations of ketoconazole dosing on the single-dose pharmacokinetics of midazolam: shortening the paradigm" J Clin Pharmacol (2009) 10.1177/0091270008331133

[38]

Takahashi "Naloxone reversal of opioid anesthesia revisited: clinical evaluation and plasma concentration analysis of continuous naloxone infusion after anesthesia with high-dose fentanyl" J Anesth (2004) 10.1007/s00540-003-0214-4

[39]

2014 http://www.medicines.org.uk/emc/medicine/17086/SPC/Durogesic + DTrans + 12 + 25 + 50 + 75 + 100 + mcg + hr + Transdermal + Patch/ http://www.medicines.org.uk/emc/medicine/17086/SPC/Durogesic + DTrans + 12 + 25 + 50 + 75 + 100 + mcg + hr + Transdermal + Patch/

[40]

Holley "Postoperative analgesia with fentanyl: pharmacokinetics and pharmacodynamics of constant-rate i.v. and transdermal delivery" Br J Anaesth (1988) 10.1093/bja/60.6.608

[41]

Portenoy "Transdermal fentanyl for cancer pain. Repeated dose pharmacokinetics" Anesthesiology (1993) 10.1097/00000542-199301000-00007

[42]

Je "Expression of CYP3A in chronic ethanol-fed mice is mediated by endogenous pregnane X receptor ligands formed by enhanced cholesterol metabolism" Arch Toxicol (2014)

Metrics

53

Citations

42

References

Details

Published: Feb 16, 2015
Vol/Issue: 55(6)
Pages: 708-717
License: View

Authors

V

Victoria C. Ziesenitz

Department of Clinical Pharmacology and Pharmacoepidemiology; University Hospital Heidelberg; Heidelberg Germany

S

Sonja K. König

Department of Clinical Pharmacology and Pharmacoepidemiology; University Hospital Heidelberg; Heidelberg Germany

N

Nina S. Mahlke

Institute of Legal and Traffic Medicine; University Hospital Heidelberg; Heidelberg Germany

G

Gisela Skopp

Institute of Legal and Traffic Medicine; University Hospital Heidelberg; Heidelberg Germany

W

Walter E. Haefeli

Department of Clinical Pharmacology and Pharmacoepidemiology; University Hospital Heidelberg; Heidelberg Germany

G

Gerd Mikus

Department of Clinical Pharmacology and Pharmacoepidemiology; University Hospital Heidelberg; Heidelberg Germany

Cite This Article

Victoria C. Ziesenitz, Sonja K. König, Nina S. Mahlke, et al. (2015). Pharmacokinetic interaction of intravenous fentanyl with ketoconazole. The Journal of Clinical Pharmacology, 55(6), 708-717. https://doi.org/10.1002/jcph.469

Pharmacokinetic interaction of intravenous fentanyl with ketoconazole

You May Also Like